PURPOSE: To study a passive targeting strategy, via the enhanced permeability and retention effect following systemic administration of lipid nanocapsules (LNCs) loaded with ferrociphenol, FcdiOH. METHODS: Long chains of polyethylene glycol (DSPE-mPEG2000) were incorporated onto the surface of LNCs by post-insertion technique. Stealth properties of LNCs were investigated by in vitro complement consumption and macrophage uptake, and in vivo pharmacokinetics in healthy rats. Antitumour effect of FcdiOH-loaded LNCs was evaluated in subcutaneous and intracranial 9L gliosarcoma rat models. RESULTS: LNCs and DSPE-mPEG2000-LNCs presented low complement activation and weak macrophage uptake. DSPE-mPEG2000-LNCs exhibited prolonged half-life and extended area under the curve in healthy rats. In a subcutaneous gliosarcoma model, a single intravenous injection of FcdiOH-LNCs (400 μL, 2.4 mg/rat) considerably inhibited tumour growth when compared to the control. DSPE-mPEG2000-FcdiOH-LNCs exhibited a strong antitumour effect by nearly eradicating the tumour by the end of the study. In intracranial gliosarcoma model, treatment with DSPE-mPEG2000-FcdiOH-LNCs and FcdiOH-LNCs statistically improved median survival time (28 and 27.5 days, respectively) compared to the control (25 days). CONCLUSION: These results demonstrate the interesting perspectives for the systemic treatment of glioma thanks to bio-organometallic chemotherapy via lipid nanocapsules.
PURPOSE: To study a passive targeting strategy, via the enhanced permeability and retention effect following systemic administration of lipid nanocapsules (LNCs) loaded with ferrociphenol, FcdiOH. METHODS: Long chains of polyethylene glycol (DSPE-mPEG2000) were incorporated onto the surface of LNCs by post-insertion technique. Stealth properties of LNCs were investigated by in vitro complement consumption and macrophage uptake, and in vivo pharmacokinetics in healthy rats. Antitumour effect of FcdiOH-loaded LNCs was evaluated in subcutaneous and intracranial 9L gliosarcomarat models. RESULTS: LNCs and DSPE-mPEG2000-LNCs presented low complement activation and weak macrophage uptake. DSPE-mPEG2000-LNCs exhibited prolonged half-life and extended area under the curve in healthy rats. In a subcutaneous gliosarcoma model, a single intravenous injection of FcdiOH-LNCs (400 μL, 2.4 mg/rat) considerably inhibited tumour growth when compared to the control. DSPE-mPEG2000-FcdiOH-LNCs exhibited a strong antitumour effect by nearly eradicating the tumour by the end of the study. In intracranial gliosarcoma model, treatment with DSPE-mPEG2000-FcdiOH-LNCs and FcdiOH-LNCs statistically improved median survival time (28 and 27.5 days, respectively) compared to the control (25 days). CONCLUSION: These results demonstrate the interesting perspectives for the systemic treatment of glioma thanks to bio-organometallic chemotherapy via lipid nanocapsules.
Authors: D L Emerson; R Bendele; E Brown; S Chiang; J P Desjardins; L C Dihel; S C Gill; M Hamilton; J D LeRay; L Moon-McDermott; K Moynihan; F C Richardson; B Tomkinson; M J Luzzio; D Baccanari Journal: Clin Cancer Res Date: 2000-07 Impact factor: 12.531
Authors: Jai Woong Seo; JooChuan Ang; Lisa M Mahakian; Sarah Tam; Brett Fite; Elizabeth S Ingham; Janine Beyer; John Forsayeth; Krystof S Bankiewicz; Ting Xu; Katherine W Ferrara Journal: J Control Release Date: 2015-10-05 Impact factor: 9.776
Authors: Tavarekere N Nagaraja; Rasha Elmghirbi; Stephen L Brown; Lonni R Schultz; Ian Y Lee; Kelly A Keenan; Swayamprava Panda; Glauber Cabral; Tom Mikkelsen; James R Ewing Journal: Magn Reson Imaging Date: 2017-09-05 Impact factor: 2.546
Authors: Bharath Ramaswamy; Sandip D Kulkarni; Pablo S Villar; Richard S Smith; Christian Eberly; Ricardo C Araneda; Didier A Depireux; Benjamin Shapiro Journal: Nanomedicine Date: 2015-06-24 Impact factor: 5.307
Authors: Nabila A El-Sheridy; Riham M El-Moslemany; Alyaa A Ramadan; Maged W Helmy; Labiba K El-Khordagui Journal: Drug Deliv Date: 2021-12 Impact factor: 6.819